| CD155 Expression in Acute Myeloid Leukemia (NCT06369662) | Assiut University | 2022-07-01 |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies (NCT05327023) | National Cancer Institute (NCI) | 2022-05-23 |
| Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil (NCT05256537) | Ronald Paquette | 2022-04-26 |
| Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey (NCT05061095) | UNC Lineberger Comprehensive Cancer Center | 2022-03-21 |
| Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) (NCT04448184) | Ottawa Hospital Research Institute | 2022-02-16 |
| Mindfulness-based Virtual Reality Intervention (NCT05602051) | Nanjing University of Traditional Chinese Medicine | 2021-11-01 |
| Immunological Profile for Patients Treated With CAR-T Cells (NCT05054231) | Institut Paoli-Calmettes | 2021-10-05 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175) | National Cancer Institute (NCI) | 2021-09-23 |
| Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy (NCT04275154) | University of Nebraska | 2021-05-25 |
| Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden (NCT04760184) | Uppsala University | 2021-04-01 |
| Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals (NCT04871165) | Vilnius University | 2021-03-24 |
| Prospective Validation of the OHI Index (NCT05882175) | Meir Medical Center | 2021-03-03 |
| Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation (NCT04691284) | National Cancer Institute, Slovakia | 2021-03-01 |
| Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant (NCT04323605) | University Hospital, Toulouse | 2021-01-01 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation (NCT03680092) | Dimitrios Tzachanis, MD PhD | 2019-11-26 |
| Optimizing PTCy Dose and Timing (NCT03983850) | National Cancer Institute (NCI) | 2019-07-09 |
| Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA (NCT04264767) | Nucleix Ltd. | 2019-04-17 |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma (NCT03908138) | Shandong Provincial Hospital | 2019-03-30 |
| Bleeding In Thrombocytopenia Explained (NCT03505086) | Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research | 2018-12-04 |
| Early Palliative Care and Hematological Cancer Patients (NCT03743480) | Azienda USL Reggio Emilia - IRCCS | 2018-11-21 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System (NCT03648372) | Takeda | 2018-10-01 |
| Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) (NCT03483194) | Weprom | 2018-09-06 |
| Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT (NCT03575767) | Affiliated Hospital to Academy of Military Medical Sciences | 2018-05-08 |
| Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia (NCT03288441) | Maastricht University Medical Center | 2018-03-20 |
| The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients (NCT04303091) | Dr. Nicole Culos-Reed | 2018-03-02 |
| Therapeutic Education in Physical Activity (ETAF) (NCT03403075) | Azienda USL Reggio Emilia - IRCCS | 2018-01-01 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT (NCT03320915) | Seoul National University Hospital | 2017-10-01 |
| Mind-body Medicine for Patients With Malignant Hematological Diseases (NCT03735992) | Universität Duisburg-Essen | 2017-09-06 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Genomic Testing and Resulting Medical Decisions (NCT03301493) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2017-03-30 |
| Shared Health Information System for Febrile Neutropenia (NCT03087227) | Marie-Helene METZGER | 2017-02-22 |
| Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients (NCT02944045) | Assistance Publique - Hôpitaux de Paris | 2017-02-15 |
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study (NCT02958462) | Mayo Clinic | 2017-01-16 |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy (NCT02895529) | Xian-Janssen Pharmaceutical Ltd. | 2016-11-30 |
| Impact of Pulmonary Follow-up After Stem Cell Graft (NCT03349372) | Hospices Civils de Lyon | 2016-11-01 |
| Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study (NCT02650791) | Ottawa Hospital Research Institute | 2016-10-01 |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant (NCT02477878) | Bellicum Pharmaceuticals | 2016-07-01 |
| UWCCC Molecular Tumor Board Registry (NCT03023202) | University of Wisconsin, Madison | 2016-03-30 |
| Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients (NCT02623309) | Institut Paoli-Calmettes | 2016-02-23 |
| Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens (NCT02635984) | Augusta University | 2015-11-01 |
| TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia (NCT03136445) | NHS Blood and Transplant | 2015-06-01 |
| A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies (NCT02329847) | Janssen Research & Development, LLC | 2015-03-11 |
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) (NCT02193880) | Ayman Saad | 2014-10-09 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (NCT02061761) | Bristol-Myers Squibb | 2014-03-13 |
| Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units (NCT02504047) | University of Calgary | 2014-02-01 |
| Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation (NCT01915498) | Celgene | 2013-08-27 |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator (NCT01802879) | Novartis Pharmaceuticals | 2013-06-24 |
| Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy (NCT01869218) | University of Colorado, Denver | 2013-04-02 |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (NCT01244906) | Northside Hospital, Inc. | 2010-12-01 |
| Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation (NCT01275534) | University Hospital, Basel, Switzerland | 2010-11-01 |
| National Marrow Donor Program Long-Term Donor Follow-Up (NCT01362179) | Center for International Blood and Marrow Transplant Research | 2010-10-01 |
| Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors (NCT01374841) | European Institute of Oncology | 2010-08-01 |
| Intra-bone Cord Blood Transplantation (NCT01332006) | Università degli Studi di Brescia | 2009-11-01 |
| Trial of Pimasertib in Hematological Malignancies (NCT00957580) | EMD Serono | 2009-09-30 |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States (NCT00997386) | University of Arizona | 2009-09-01 |
| Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies (NCT00914849) | Washington University School of Medicine | 2009-08-01 |
| The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants (NCT01021683) | Janssen Korea, Ltd., Korea | 2009-07-01 |
| Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer (NCT00900614) | Aprea Therapeutics | 2009-05-01 |
| A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. (NCT00623870) | Hoffmann-La Roche | 2008-05-01 |
| Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors (NCT00618969) | University of Arizona | 2008-02-01 |
| Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies (NCT00595686) | Esanex Inc. | 2008-01-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation (NCT00750126) | University Hospital, Clermont-Ferrand | 2007-04-01 |
| Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers (NCT00421213) | Alaunos Therapeutics | 2006-12-01 |
| Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. (NCT00389428) | Jazz Pharmaceuticals | 2006-09-01 |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00698685) | University of Arizona | 2006-01-23 |
| Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion (NCT00987987) | Assistance Publique - Hôpitaux de Paris | 2005-12-01 |
| Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients (NCT00473577) | Pharmacyclics LLC. | 2005-08-01 |
| Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members (NCT00071045) | National Heart, Lung, and Blood Institute (NHLBI) | 2003-10-08 |
| A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation (NCT00067730) | Eli Lilly and Company | 2003-03-01 |
| Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers (NCT00051311) | National Cancer Institute (NCI) | 2003-01-03 |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer (NCT00312429) | Duke University | 2002-01-01 |
| Clofarabine in Chronic Lymphocytic Leukemia (NCT00028418) | M.D. Anderson Cancer Center | 1999-02-01 |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies (NCT00001748) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies (NCT00038376) | M.D. Anderson Cancer Center | 1990-05-08 |
| Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma (NCT00044759) | Wyeth is now a wholly owned subsidiary of Pfizer | |